The present invention relates to a novel strain of Trichoderma comprising genetic modifications that enable the improved production of an enzyme cocktail, involving at least upregulation of the transcription factor Xyr1 according to SEQ ID No. 1; disruption of the gene ACE1 according to SEQ ID No. 2; disruption of the gene SLP1 according to SEQ ID No. 3; and expression of the gene Cel3a from Rasamsonia emersonii according to SEQ ID No. 4.

An automatic dishwashing cleaning composition having a new protease.

An automatic dishwashing cleaning composition having a new protease.

The present disclosure concerns a method for producing peptides such as glutathione and a microorganism that can be used for such method. One or more embodiments of the first aspect of the present disclosure concern a method for producing peptides such as glutathione comprising culturing a prokaryotic microbial strain in which the expression levels of one or more genes selected from among the gshA gene, the gshB gene, and the gshF gene are enhanced, compared with the expression levels thereof in the wild-type strain thereof in a medium in which the total concentration of cysteine and cystine is 0.5 g/l or lower. The second aspect of the present disclosure concerns a microorganism comprising disruptions of the γ-glutamyltransferase gene and the glutathione reductase gene and exhibiting the enhanced expression levels of the gshA gene and the gshB or gshF gene.

Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

The present invention relates to the fields of genetic engineering and fermentation engineering, and provides a Candida utilis double gene co-expression strain for hydrolyzing protein components in kitchen waste, in which the Candida utilis double gene co-expression strain is constructed by integrating carboxypeptidases and endoprotease genes through a Candida utilis expression vector onto a Candida utilis genome. The present invention further provides a Candida utilis double gene co-expression strain capable of degrading kitchen waste, specifically degrading the protein components in the kitchen waste, and decomposing and transforming the proteins into small peptides and amino acids.

The present invention relates to materials and methods for engineering, expression and high-level production of cost effective, safe and functional active recombinant truncated human Angiotensin-converting enzyme 2 (ACE2) in plants using transient expression system. In particular, the present invention relates to the production of glycosylated and non-glycosylated forms of ACE2 polypeptide in Nicotiana benthamiana (N. benthamiana) plant. The cost effective, safe and functional active plant produced recombinant ACE2 polypeptides can be used as a potential therapeutic target in COVID-19 patients to block or slow down the virus entering, spread of the virus and protect the lung from injury, also recombinant ACE2 enzymes are used as potential drugs to treat patients by controlling blood pressure.

Fusion proteins with immunoglobulin binding properties, their uses and related methods and compositions are disclosed. The fusion proteins are comprised of an antibody-binding fragment of protein M from Mycoplasma spp. conjugated to a receptor fragment. The receptor fragment is a protein fragment to which a pathogen, a toxin or a cancer cell can specifically bind. The fusion proteins can be used to neutralize or eradicate a wide group of pathogens, toxins or cancer cells.

Angiotensin-converting enzyme 2 (ACE2) has been confirmed as a specific receptor for several (3 group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.

Provided herein are multivalent particles and compositions of multivalent particles for blocking viral infection.